The pharmaceutical and biotechnology industries are actively developing combination drugs to increase ease of administration and treatment effectiveness. We are actively responding to the demand as the preference for combination medicines that are convenient to take is increasing among people with chronic diseases who need to take medicine every day. There is also a goal to secure market share by strengthening various dosages and ingredients.
According to the pharmaceutical and bio industry on the 22nd, Daewoong Pharmaceutical is preparing to launch ‘Enblomet,’ a combination drug that adds metformin, an existing diabetes treatment, to its new diabetes drug, Enblo. In addition, Daewoong Pharmaceutical also applied for a long-term phase 3 clinical trial for a three-drug combination in which Enblo and two other diabetes drugs will be administered together for one year.
Boryung (formerly Boryung Pharmaceutical) recently received approval from the Ministry of Food and Drug Safety for phase 3 clinical trials for ‘BR1018,’ a combination drug for hypertension and dyslipidemia. The treatment is a four-drug combination that adds amlodipine, atorvastatin, and ezetimibe to pimasartan, the main ingredient in ‘Kanab’, a new drug for high blood pressure developed by Boryung.
Pimasartan is a high blood pressure treatment drug (kanarb single ingredient), and ‘amlodipine’, a ‘high blood pressure treatment drug’ that suppresses the rise in blood pressure by blocking calcium ions from flowing into the heart muscle, has been added to it. It also included ‘atorvastantin’, a drug to treat hyperlipidemia, and ezetimibe, a drug that prevents cholesterol from being absorbed back into the body from the small intestine. A Boryeong official explained, “This new improved drug is a combination drug that contains four ingredients in one drug to provide various treatment options and improve medication compliance.”
He continued, “Among the Kanarb family, the fimasartan/amlodipine combination is sold as a product called ‘Ducarb,’ and pimasartan and atorvastantin are sold as a product called ‘Acarb.’” Boryung is currently developing additional cannab combination drugs in various combinations, such as ‘BR1015’, a combination drug for high blood pressure, and ‘BR1017’, a combination drug for hypertension and dyslipidemia, and is also applying for a phase 3 clinical trial plan for ‘BR1019’, a combination drug that treats hypertension and diabetes simultaneously. Active in the development of combination drugs.
Dongkook Pharmaceutical also recently confirmed the efficacy and safety of ‘DKF-313’, a combination drug for benign prostatic hyperplasia, in phase 3 clinical trials. DKF-313 is a combination of ‘Dutasteride’, a treatment for benign prostatic hyperplasia, and ‘Tadalafil’, a treatment for male erectile dysfunction that is effective in improving urinary disorder symptoms. According to Dongkook Pharmaceutical, except for one product from a multinational pharmaceutical company, there are no combination drugs for benign prostatic hyperplasia. An official from Dongkook Pharmaceutical explained, “Through the dual effect of the combination drug, we can expect a superior treatment effect than a single drug, and the quality of life of chronic disease patients will improve as they only need to take one pill once a day.”
An official in the pharmaceutical industry said, “As the number of chronically ill patients taking multiple medications at once increases, pharmaceutical companies are developing three- and four-drug combinations to improve medication convenience and treatment effectiveness.” He went on to say, “If we create a composite material, we can gain a little more of an edge over the generic competition. This is because we can secure competitiveness by reducing the pill size, strengthening the ingredients, or changing them to ensure faster absorption.” Reporter Kang Min-seong kms@dt.co.kr
Daewoong Pharmaceutical provides diabetes treatment ‘Enblo Tablet’.
[ 저작권자 ⓒ디지털타임스, 무단 전재 및 재배포 금지 ]
2023-10-22 05:04:00
#combined #stronger…Pharmaceutical #industry #working #hard #develop #combined #drugs #diabetes #high #blood #pressure
